> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# MIM Software’s Molecular Radiotherapy Dosimetry Cleared
- URL: https://www.fdaweb.com/mim-softwares-molecular-radiotherapy-dosimetry-cleared/
- Published: 2019-01-16T12:00:00.000Z
- Updated: 2026-09-15T00:54:43.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5143161

FDA has cleared an MIM Software Inc. 510(k) for its molecular radiotherapy (MRT) dosimetry. MRT uses radiopharmaceuticals such as Lutathera (Lu-177 DOTATATE) and Azedra (I-131 iobenguane) to target tumors based on certain receptors that these tumors express. Currently, the company says there has not been an effective way to measure the absorbed dose from MRT for an individual patient. “This is due to a lack of access to quantitative SPECT images and tools for calculating dose on the patient’s own anatomy,” it says. MIM’s MRT is designed to provide both quantitative SPECT reconstruction and voxel-based absorbed dose calculation by using the patient’s own images, allowing for personalized dosimetry measurements, MIM explains. The device provides tools for organ and tumor segmentation, deformable registration, multi-tracer theranostics support, planar corrections, and dosimetry reporting tools.